Medical/Pharmaceuticals
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer
SUZHOU, China, Oct. 27, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC P...
2025-10-27 09:51
1044
Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025
SHANGHAI and HONG KONG, Oct. 27, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune dis...
2025-10-27 09:00
1258
Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
* The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group * DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head c...
2025-10-27 08:00
1188
Real-World Data Presented at TCT 2025 Demonstrates the EggNest™ Complete Radiation Protection System Significantly Reduces Radiation Exposure for the Entire Cath Lab Team
SAN FRANCISCO, Oct. 26, 2025 /PRNewswire/ -- At the 2025 Transcatheter Cardiovascular Therapeutics® (TCT) Conference, Dr.Jarrod Frizzell of The Christ Hospital (Cincinnati, OH) presented real-world studies¹,² demonstrating that the EggNest™ Complete Radiation Protection System from Egg Medical, In...
2025-10-27 01:00
1436
WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance
* Q3 Total Revenue: RMB12.06 Billion, Up 15.3% YoY; * Revenue from Continuing Operations[1] Reached RMB12.04 Billion, Up 19.7% YoY * Q1-Q3 Total Revenue: RMB32.86 Billion, Up 18.6% YoY; * Revenue from Continuing Operations Reached RMB32.45 Billion, Up 22.5% YoY * Q1-Q3 Net Profit Attributa...
2025-10-26 15:53
4328
Indonesia's Legacy in the Global Vaccine Landscape, Bio Farma and DCVMN Strengthen Health Resilience Through Global Partnership
BANDUNG, Indonesia, Oct. 25, 2025 /PRNewswire/ -- Through PT Bio Farma (Persero),Indonesia has played a strategic and sustained role in the Developing Countries Vaccine Manufacturers' Network (DCVMN), working to ensure equitable access to safe, high-quality, and affordable vaccines. Since DCVMN's...
2025-10-25 18:52
2609
MHTC WELCOMES ROYAL OMAN POLICE TO ENHANCE GOVERNMENT-TO-GOVERNMENT COOPERATION
KUALA LUMPUR, Malaysia, Oct. 25, 2025 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) concluded a four-day familiarisation visit by seniorRoyal Oman Police (ROP) officials from 21 to 24 October 2025. The delegation, led by Brigadier DrNaseer Al-Manthery, Director General of Medical Serv...
2025-10-25 17:04
2589
Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company") today announced the successful completion of pa...
2025-10-25 15:00
2538
MindHYVE.ai™ and Prime Institute of Health Sciences (PIHS) Launch Landmark AI Partnership to Transform Education and Healthcare in Pakistan
ISLAMABAD, Oct. 25, 2025 /PRNewswire/ -- MindHYVE.ai™, a global leader in agentic artificial intelligence and adaptive learning technologies, has announced a landmark partnership with the Prime Institute of Health Sciences (PIHS) inIslamabad, marking a defining milestone in Pakistan's AI transfo...
2025-10-25 02:18
2625
Beyond Recovery: QUINEAR QN-071A Brings Professional Compression Therapy Home for Holiday Deals
NEW YORK, Oct. 24, 2025 /PRNewswire/ -- When recovery becomes the new performance edge. True progress doesn't happen during exertion — it begins in recovery. For years, QUINEAR has led the evolution of professional-grade compression systems, making clinical technology accessible to everyday athl...
2025-10-25 00:07
1601
Embracing the Gift of Life, Healing Little Hearts Together
Pantai Hospital Kuala Lumpur and Shangri-La Kuala Lumpur Unites Again to Support Children with Congenital Heart Disease for the Second Year KUALA LUMPUR, Malaysia, Oct. 24, 2025 /PRNewswire/ -- In a powerful display of compassion, purpose, and partnership, Pantai Hospital Kuala Lumpur (PHKL) and...
2025-10-24 22:04
2167
A Self-Reliant Future through HPV 9-Valent Vaccine Alliance: INNOVAX details Localization Strategy in Thailand at IPVS 2025
BANGKOK, Oct. 24, 2025 /PRNewswire/ -- On October 23, 2025, Dr. Zhiming ( Tiffany) Jiang, General Manager of Wantai Group, and Dr. Huirong (Harry) Pan, General Manager of Xiamen Innovax Biotech Co., Ltd. ("Innovax"), participated in the 37th International Papillomavirus Society (IPVS) Conference i...
2025-10-24 20:20
1632
Terumo Interventional Systems Announces Its New OPUSWAVE® Dual Sensor Imaging System and DualView® Imaging Catheter Receive FDA 510(k) Clearance
* OPUSWAVE Imaging System combines OFDI and IVUS into a single catheter, providing significant potential to reduce procedural time and costs in treating coronary artery disease * DualView imaging catheter offers a 150mm maximum pullback length, a 2.6 Fr. imaging profile, 6 Fr. guide compatibi...
2025-10-24 20:00
1223
The Future of Life Sciences, Omics and AI Examined by Leading Global Genomic Experts
Groundbreaking Human-Centric Genomic Foundation Model Unveiled HANGZHOU, China, Oct. 24, 2025 /PRNewswire/ -- The future of Omics and AI in life sciences is the central theme for more than 100 scientists and guests from 19 countries and regions gathered inHangzhou, China, for the 20th Annual Mee...
2025-10-24 18:13
1199
Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection
BEIJING and GOTHENBURG, Sweden, Oct. 24, 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis D Virus (HDV) infec...
2025-10-24 18:12
2258
Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore
* The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics inOctober 2025 for individuals 6 months of age and older. SINGAPORE, Oct. 24, 2025 /PRNewswire/ -- Pfizer Singapore and BioNTech SE (Nasdaq: BNTX, "BioNT...
2025-10-24 17:33
1330
Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website
SHANGHAI, Oct. 24, 2025 /PRNewswire/ -- At 15:00 Beijing Time (09:00 am Berlin Time) onOctober 20, the "Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) Nasopharyngeal Carcinoma BL-B01D1-303 Research Results" was held at the venue of the 2025 European Society for Medical Oncology (ESMO...
2025-10-24 16:40
951
Gushengtang TCM and 1doc Form Strategic Partnership to Establish Singapore's Integrated TCM Service Model
SINGAPORE, Oct. 24, 2025 /PRNewswire/ -- Gushengtang TCM officially launched its "Master TCM AI" system at GovWare 2025 onOctober 22. The launch coincides with a strategic partnership with 1doc and a signed agreement with August Global Partners (AGP) for strategic investment, supporting the shift...
2025-10-24 15:08
1129
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022
SUZHOU, China, Oct. 24, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I clinical study (Study ID: JSKN022-101) of JSKN022, an independently developed innovative bispeci...
2025-10-24 12:56
1167
HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity
FACO 2025 presentation highlights HCB101's favorable safety, strong receptor occupancy, and confirmed responses in patients with advanced cancers. TAIPEI, SHANGHAI, and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advanci...
2025-10-24 07:30
1834
Week's Top Stories
Most Reposted
Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience
[Picked up by 309 media titles]
2026-01-15 13:00Ready Server Announces Strategic Expansion into Japan with AT TOKYO Data Centre
[Picked up by 301 media titles]
2026-01-13 13:16
JIOS Aerogel® Secures Hyundai Contract Through New Licensing Model
[Picked up by 296 media titles]
2026-01-15 10:00Infobip strengthens leadership to drive growth and innovation
[Picked up by 280 media titles]
2026-01-16 11:00
Docquity Launches Engage™, an AI and Insights-Powered HCP Intelligence Engine for the Life Sciences Industry
[Picked up by 278 media titles]
2026-01-15 13:00Most Read
GIGABYTE Strengthens NVIDIA® Partnership to Drive Innovation in AI-Powered Gaming and Creative Solutions
2026-01-17 00:00
5933
